Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Webcasts|October 22, 2024

Advanced Analytical Methods for Oligonucleotide ID Testing in Pharmaceuticals QC

Author(s)Agilent

Webinar Date/Time: Session 1: Tues, Dec 5, 2024, at 12:00 PM BST | 1:00 PM CET Session 2: Tues, Dec 5, 2024, at 11:00 AM PST | 2:00 PM EST | 7:00 PM GMT Session 3: Wed, Dec 6, 2024, at 9:30 AM IST | 12:00 PM SGT | 1:00 PM JST | 3:00 PM AEDT

This webinar will focus on the sequence-specific method and provide a deep dive into the UV-spectrometric determination of the oligonucleotide melting temperature (Tm) using the Agilent Cary 3500 UV-Vis after a short introduction to oligonucleotides.

Register Free: https://www.spectroscopyonline.com/spec_w/advanced-analyticals

Event Overview:

In the pharmaceutical industry, all starting materials and the active pharmaceutical ingredients (APIs) of a drug product must be subjected to analytical identity (ID) testing as part of the release prior to their introduction into the pharmaceutical manufacturing process. For quality control laboratories in general—and particularly for a contract development and manufacturing organization (CDMO) handling a wide variety of materials—it is preferable to perform ID tests using a simple, fast, highly specific analytical method. This preference also applies to oligonucleotides, an emerging class of APIs, where a combined ID testing strategy should be applied, including intact mass determination and a sequence-specific method.

After a short introduction to oligonucleotides, this webinar will focus on the sequence-specific method and provide a deep dive into the UV-spectrometric determination of the oligonucleotide melting temperature (Tm) using the Agilent Cary 3500 UV-Vis.


Key Learning Objectives:

  • Recognize the fundamentals of oligonucleotide melting temperature analysis
  • Identify analytical characteristics, potential pitfalls, and how to avoid them
  • Learn how the multicell peltier module add-on helps increase efficiency by collecting multiple samples simultaneously
  • Understand how an in-cuvette temperature probe with built-in magnetic stirrers improves data quality
  • Learn about software built-in features such as smoothing and derivative that can enhance data quality

Who Should Attend:

  • Analytical scientists and technicians interested in UV-Vis technologies
  • Researchers in oligonucleotides fields
  • Quality control specialists for ID testing
  • Laboratory managers interested in analytical innovations


Speakers:

Alexandra H. Heussner, PhD
Laboratory Manager
Analytical Science Laboratory
Vetter Pharma

Register Free: https://www.spectroscopyonline.com/spec_w/advanced-analyticals


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.